Global Hepatocellular Carcinoma Drugs Market Overview
Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that originates from liver cells or hepatocytes. The disease occurs mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity and diabetes. The diagnosis of hepatocellular carcinoma is mainly performed by imaging tests such as ultrasound, magnetic resonance, computed tomography and liver biopsy. The treatment of hepatocellular carcinoma mainly includes radiotherapy, ablation therapy in addition to chemotherapy and targeted pharmacological therapy. The majority of HCC patients are diagnosed at the final stage of liver dysfunction. Due to the poor prognosis of the disease, the mortality rate is approximately the same as the incidence rate. Therefore, early detection of cancer is an important parameter to improve the survival of affected patients, which contributes to the growth of the global market for hepatocellular carcinoma drugs.
Browse report brief and TOC @ https://www.researchcosmos.com/reports/global-hepatocellular-carcinoma-drugs-market-outlook-2022-trends-and-developments/3380784
Global Hepatocellular Carcinoma Drugs Market Drivers and Restraints:
The increasing incidence of cases of global hepatocellular carcinoma is an important factor that increases market growth. According to research by International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common cancer in the world and the third most common cause of death in the world found in one-fifth of men and -eight of women. In addition, according to the University of Addis Ababa, 2017, hepatocellular carcinoma (HCC) accounts for 854,000 new cases of liver cancer and 810,000 deaths in 2015. In addition, the increase in the incidence and mortality of Hepatocellular carcinoma is attributed to the emergence of new risk factors such as viral hepatitis B and C, metabolic disorders such as diabetes and fatty liver disease and exposure to non-alcoholic toxins such as alcohol and aflatoxins. In addition, the clinical advances incorporated in regulatory approvals for new drugs to treat hepatocellular carcinoma increase the growth of the market. For example, in April 2017, the US Food and Drug Administration has extended the indications for regorafenib (Stivarga) manufactured by Bayer HealthCare Pharmaceuticals Inc., for the treatment of patients with hepatocellular carcinoma. The therapy showed a significant improvement in patient survival after failure of standard treatments. In addition, in 2017, the US FDA approved accelerated drug nivolumab (Opdivo) developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma.
However, side effects associated with medications such as anemia, constipation, low white blood cell count, pneumonia, etc. may limit the growth of the market.
Request free sample @ https://www.researchcosmos.com/request/global-hepatocellular-carcinoma-drugs-market-outlook-2022/3380784
On the basis of geography, Global Hepatocellular Carcinoma Drugs Market is segmented into regions such as North America, Latin America, Europe, Middle East and Africa and Asia Pacific. North America is expected to maintain its dominant position in the global market for hepatocellular carcinoma due to the increasing prevalence of the disease and the increasing number of clinical trials conducted by manufacturers to meet medical needs. According to the University of California Los Angeles (UCLA) Department of Health Sciences survey in 2017, hepatocellular carcinoma (HCC) accounts for three-quarters of all liver cancers in the United States. With approximately 40,000 Americans diagnosed with liver cancer in 2017 and more than 28,000 deaths reported by the disease. In addition, in April 2018, Eli Lilly and Company completed the Phase 3 study of Cyramza (ramucirumab) as a unique agent in the second-line treatment of people with hepatocellular carcinoma, also known as liver cancer.
Asia-Pacific is expected to enter the global market for hepatocellular carcinoma medications due to the growing number of research and development activities by manufacturers in the region to develop effective therapies. For example, in February 2017, Daiichi Sankyo, a pharmaceutical company in Japan, completed the phase 3 study of tivantinib indicated for patients with hepatocellular carcinoma treated with other therapies.
Key Players in Global Hepatocellular Carcinoma Drugs Market:
Major players competing in Global Hepatocellular Carcinoma Drugs Market include Bayer AG, Novartis Pharmaceuticals, Bristol-Myers Squibb Company, Merck & Co., Inc., Johnson & Johnson, AbbVie Inc., Amgen Inc., Celgen Corporation, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd. and others.
Inquire Before Buying @ https://www.researchcosmos.com/inquire/global-hepatocellular-carcinoma-drugs-market-outlook-2022/3380784
Scope of the report:
The report offers a comprehensive analysis of the industry by providing the estimations of market potential and forecasts with utmost granularity. Along this, the factors influential in effecting the market dynamics and trends are discussed in detail at the product level. Further, the performance of the market at the regional and country-level is assessed and the prospects with high growth potential are identified and debated.
The key players in the industry are profiled providing insights on their financial performance, market position and growth strategies. Comparative analysis on prime strategical activities of the market players delineating the key developments like mergers & acquisitions, collaborations and an evaluation of the competitive environment within the industry are provided. The report also offers a broad outlook of the market along with recommendations from industry experts on the opportunities for investment activity.
What else? Apart from the syndicated report, our in-house team has an expertise and experience in designing custom reports to meet your specific research needs and assist you in making well-informed decisions.
Research Cosmos is a provider of standard and customized market research, business intelligence and consulting services across more than 100 domains in different industries of the world. We host the trending market reports of the world’s top-notch publishing companies, offering services to a wide range of customers from students to fortune 500 companies and discloses the hidden opportunities in every leading industry of the world.
Global Sales Manager
+1 888 709 8757